PainReformPRFX
Market Cap: $867K
About: PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
Employees: 7
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1.89% more ownership
Funds ownership: 10.3% [Q1] → 12.19% (+1.89%) [Q2]
0% more funds holding
Funds holding: 4 [Q1] → 4 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
55% less capital invested
Capital invested by funds: $324K [Q1] → $145K (-$179K) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Maxim Group Naz Rahman 11% 1-year accuracy 1 / 9 met price target | 1,521%upside $12 | Buy Reiterated | 26 Jun 2024 |
Financial journalist opinion
Based on 3 articles about PRFX published over the past 30 days